PERSON
Cityblock Health Appoints New CTO and Tech-Focused Board Members to Accelerate AI-Driven Care
Cityblock Health; CTO; Alberto Lopez Toledo; board members; AI; Medicaid
Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics
Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C
Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26
Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide
Lightning Step and Sunwave Achieve SOC 2 Type II Attestation, Strengthening Security and Trust Across Healthcare Technology
Lightning Step; Sunwave; SOC 2 Type II; Healthcare Technology; Security; Compliance
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech
Sentynl Therapeutics Receives FDA Approval for ZYCUBO, First US Treatment for Rare Menkes Disease
Sentynl Therapeutics; ZYCUBO; FDA approval; Menkes disease; copper histidinate; Zydus Lifesciences
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Pfizer; Obesity Drugs; Metsera; Phase III Trials; Albert Bourla; JPM26; Patent Cliff
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus
BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos
FDA Lifts Partial Hold on Merck and Daiichi Sankyo’s B7-H3 ADC Trial for Lung Cancer[6]
FDA; partial hold lifted; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; B7-H3 ADC; small cell lung cancer; IDeate-Lung02
FDA Announces Flexible Manufacturing Approach for Cell and Gene Therapies on January 11, 2026
FDA; cell and gene therapies; CGT; manufacturing flexibility; CMC requirements; Marty Makary